Protein kinase C inhibition by ET-18-OCH3 and related analogs: A target for cancer chemotherapy

Advances in Experimental Medicine and Biology

Volumn 416, Issue , 1997, Pages 173-180

  Pauig, Susan B ^a   Daniel, Larry W ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DNA FRAGMENT; EDELFOSINE; ILMOFOSINE; PROTEIN KINASE C;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL DEATH; CELL DIFFERENTIATION; CELL STRAIN HL 60; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HL-60 CELLS; HUMANS; PHOSPHOLIPID ETHERS; PROTEIN KINASE C; SIGNAL TRANSDUCTION;

EID: 0030940654     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (49)

1. Blumberg, P.M., Aces, G., Areces, L.B., Kazanietz, M.G., Lewin, N.E., and Szallasi, Z. Protein kinase C in signal transduction and carcinogenesis. In: Receptor-Mediated Biological Processes: Implications for Evaluating Carcinogenesis, pp. 3-19, Wiley-Liss, Inc., 1994.
2. Kikkawa, U., Kishimoto, A., and Nishizuka, Y. The protein kinase C family: heterogeneity and its implications. Ann. Rev. Biochem., 58: 31-44, 1989.
3. Parker, P.J., Kour, G., Marais, R.M., Mitchell, F., Pears, C., Schaap, D., Stabel, S., and Webster, C. Protein kinase C-α family affair. Mol. Cell. Endo., 65: 1-11, 1989.
4. Castagna, M., Takai, Y., Kaibuchi, K., Sano, K., Kikkawa, U., and Nishizuka, Y. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumour-promoting phorbol esters. J. Biol. Chem., 257: 7847-7851, 1982.
5. Kishimoto, A., Takai, Y., Mori, T., Kikkawa, U., and Nishizuka, Y. Activation of calcium and phospholipid-dependent protein kinase by diacylglycerol, its possible relation to phosphatidylinositol turnover. J. Biol. Chem., 255: 2273-2276, 1980.
6. Kiss, Z., Deli, E., and Kuo, J.F. Temporal changes in intracellular distribution of protein kinase C during differentiation of human leukemia HL-60 cells induced by phorbol ester. FEBS Letters, 231: 41-46, 1988.
7. Nishikawa, M., Komada, F., Uemura, Y., Hidaka, H., and Shirakawa, S. Decreased expression of type II protein kinase C in HL-60 variant cells resistant to induction of cell differentiation by phorbol diester. Cancer Research, 50: 621-626, 1990.
8. Nakaki, T., Mita, S., Yamamoto, S., Nakadate, T., and Kato, R. Inhibition by palmitoylcarnitine of adhesion and morphological changes in HL-60 cells induced by 12-O-tetradecanoylphorbol-13-acetate. Cancer Research, 44: 1908-1912, 1984.
9. Macfarlane, D.E. and Manzel, L. Activation of β-isozyme of protein kinase C (PKCβ) is necessary and sufficient for phorbol ester-induced differentiation of HL-60 promyelocytes. J. Biol. Chem., 269: 4327-4331, 1994.
10. Chedid, M., Yoza, B.K., Brooks, J.W., and Mizel, S.B. Activation of AP-1 by IL-1 and phorbol esters in T cells. Role of protein kinase A and protein phosphatases. J. Immunology, 147: 867-873, 1991.
11. 3 in HL-60 cells. J. Biol. Chem., 265: 2370-2374, 1990.
12. Makowski, M., Ballester, R., Cayre, V., and Rosen, O.M. Immunochemical evidence that three protein kinase C isozymes increase in abundance during HL-60 differentiation induced by dimethyl sulfoxide and retinoic acid. J. Biol. Chem., 263: 3402-3410, 1988.
13. Hassan, H.T. Differentiation induction of therapy of acute myelogenous leukemias. Haematologia, 21: 141-150, 1988.
14. Hassan, H.T. Differentiation induction therapy: An alternative for the treatment of elderly patients with acute myelogenous leukemias. J. Clin. Exp. Gerontology., 10: 63-73, 1988.
15. Obeid, L.M., Linardic, C.M., Karolak, L.A., and Hannun, Y.A. Programmed cell death induced by ceramide. Science, 259: 1769-1771, 1993.
16. Jarvis, W.D., Fornari, F.A., Browning, J.L., Gewirtz, D.A., Kolesnick, R.N., and Grant, S. Attenuation of ceramide-induced apoptosis by diglyceride in human myeloid leukemia cells. J. Biol. Chem., 269: 31685-31692, 1994.
17. Jarvis, W.D., Povirk, L.F., Turner, A.J., Traylor, R.S., Gewirtz, D.A., Pettit, G.R., and Grant, S. Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[β-D-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells. Biochemical Pharmacology, 47: 839-852, 1994.
18. Jarvis, W.D., Turner, A.J., Povirk, L.F., Traylor, R.S., and Grant, S. Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C. Cancer Research, 54: 1707-1714, 1994.
19. Berdel, G.E. Ether lipids and derivatives as investigational anticancer drugs. Onkologie, 13: 245-250, 1990.
20. Berdel, W.E. Membrane-interactive lipids as experimental anticancer drugs. British Journal of Cancer, 64: 208-211, 1991.
21. Honma, Y., Kasukabe, T., Hozumi, M., Tsushima, S., and Nomura, H. Induction of differentiation of cultured human and mouse myeloid leukemia cells by alkyl-lysophospholipids. Cancer Research, 41: 3211-3216, 1981.
22. Rogers, M.A., Samples, L., Chabot, M.C., Marasco, C.J., Piantadosi, C., and Daniel, L.W. Leukemic cell differentiation by ether-linked lipids: studies on quarternary ammonium alkylglycerols. Proceedings of the American Association for Cancer Research, 31: 410, 1990.
23. Diomede, L., Colotta, F., Piovani, B., Re, F., Modest, E.J., and Salmona, M. Induction of apoptosis in human leukemic cells by the ether lipid 1-O-octadecyl-2-methyl-rac-glycero-3-phosphocholine: a possible basis for its selective action. Internationl Journal of Cancer, 53: 124-130, 1993.
24. Diomede, L., Piovani, B., Re, F., Principe, P., Colotta, F., and Modest, E.J. The induction of apoptosis is a common feature of the cytotoxic action of ether-linked glycerophospholipids in human leukemic cells. International Journal of Cancer, 57: 645-649, 1994.
25. Vogler, W.R., Berdel, W.E., Olson, A.C., Winton, E.F., Heffner, L.T., and Gordon, D.S. Autologous bone marrow transplantation in acute leukemia with marrow purged with alkyl-lysophospholipid. Blood, 80: 1423-1429, 1992.
26. Hoffman, D.R., Hoffman, L.H., and Snyder, F. Cytotoxicity and metabolism of alkyl phospholipid analogues in neoplastic cells. Cancer Research, 46: 5803-5809, 1986.
27. Wilcox, R. W., Wykle, R.L., Schmitt, J.D., and Daniel, L.W. The degradation of platelet activating factor and related lipids: susceptibility to phospholipases C and D. Lipids, 22: 800-807, 1987.
28. 3. Proceedings of the American Association for Cancer Research, 31: 412, 1990.
29. Chabot, M.C., Wykle, R.L., Modest, E.J., and Daniel, L.W. Correlation of ether lipid content of human leukemia cell lines and their susceptibility to 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine. Cancer Research, 49: 4441-4445, 1989.
30. Diomede, L., Bizzi, A., Magistrelli, A., Modest, E.J., Salmona, M., and Noseda, A. Role of cell cholesterol in modulating antineoplastic ether lipid uptake, membrane effects, and cytotoxicity. International Journal of Cancer, 46: 341-346, 1990.
31. Daniel, L.W. Ether lipids in experimental cancer chemotherapy. In: J.A. Hickman and T.R. Tritton (eds.), Cancer Chemotherapy, pp. 146-178, Oxford: Blackwell Scientific Publications. 1993.
32. 2+-dependent protein phosphorylation system in various types of leukemic cells from human patients and in human leukemic cell lines HL60 and K562, and its inhibition by alkyl-lysophospholipid. Cancer Research, 43: 2955-2961, 1983.
33. Parker, J., Daniel, L. W., and Waite, M. Evidence of protein kinase C invovlement in phorbol diester-stimulated arachidonic acid release and prostaglandin synthesis. J. Biol. Chem., 262: 5385-5393, 1987.
34. Shoji, M., Raynor, R.L., Berdel, W.E., Vogler, W.R., and Kuo, J.F. Effects of thioether phospholipid BM41.440 on protein kinase C and phorbol ester-induced differentiation of human leukemia HL-60 and KG-1 cells. Cancer Research, 48: 6669-6673, 1988.
35. Berdel, W.E., Fromm, M., Fink, U., Pahlke, W., Bicker, U., Reichert, A., and Rastetter, J. Cytotoxicity of thioether-lysophospholipids in leukemia and tumours of human origin. Cancer Research, 43: 5538-5543, 1983.
36. Daniel, L.W., Etkin, L.A., Morrison, B.T., Parker, J., Morris-Natschke, S., Surles, J.R., and Piantadosi, C. Ether lipids inhibit the effects of phorbol diester tumor promoters. Lipids, 22: 851-855, 1987.
37. Daniel, L.W. Protein kinase C inhibition by alkyl-linked lipids. In: J.J. Kabara (ed.), The Pharmacological Effects of Lipids, pp. 90-96, Illinois: The American Oil Chemists Society. 1990.
38. Rogers, M.A., Small, G.W., Samples, L., and Daniel, L.W. Phorbol diester stimulated HL-60 cell differentiation is associated with the activation of specific DNA binding proteins. Proceedings of the American Association for Cancer Research, 32: 295, 1991.
39. Kiss, Z., Deli, E., Vogler, W.R., and Kuo, J.F. Antileukemic agent alkyl-lysophospholipid regulates phosphorylation of distinct proteins in HL-60 and K562 cells and differentiation of HL-60 cells promoted by phorbol ester. Biochemical Biophysical Research Communications, 142: 661-666, 1987.
40. Frei, E., Bickers, J.N., Hewitt, M., Leary, W.V., and Talley, R.W. Dose schedule and antitumor studies of arabinosyl cytosine. Cancer Research, 29: 1325-1332, 1969.
41. Hassan, H.T. and Rees, J.K. Triple Combination of Retinoic acid + low concentration of cytosine arabinoside + hexamethylene bisacetamide induces differentiation of human AML blasts in primary culture. Hematological Oncology, 7: 429-440, 1989.
42. Hassan, H.T. and Rees, J.K. Low concentrations of cytosine arabinoside, 6-thioguanine, actinomycin-D and aclacinomycin A stimulate the differentiation of normal human marrow myeloid progenitor cells. Medical Oncology & Tumor Pharamcotherapy, 6: 213-217, 1989.
43. Hino, K. and Nakamaki, T. Differentiation therapy for myelodysplastic syndrome. Japanese Journal of Clinical Hematology, 34: 283-288, 1993.
44. Brach, M.A., Mertelsmann, R.H., and Herrmann, F. Modulation of cytotoxicity and differentiation-inducing potential of arabinofuranosylcytosine in myeloid leukemia cells by hematopoietic cytokines. Cancer Investigation, 11: 198-211, 1993.
45. Strum, J.C., Small, G.W., Pauig, S.B., and Daniel, L.W. 1-β-D-arabinofuranosylcytosine stimulates ceramide and diglyceride formation in HL-60 cells. J. Biol. Chem., 269: 15493-15497, 1994.
46. Kharbanda, S., Datta, R., and Kufe, D. Regulation of c-jun gene expression in HL-60 leukemia cells by 1-β-D-arabinofuranosylcytosine. Biochemistry, 30: 7947-7932, 1991.
47. Kharbanda, S., Emoto, Y., Kisaki, H., Saleem, A., and Kufe, D. 1-beta D-arabinofuranosylcytosine activates serine/threonine protein kinases and c-jun gene expression in phorbol ester-resistant myeloid leukemia cells. Molecular Pharmacology 46: 67-72, 1994.
48. Ueda, T., Imamura, S., and Kawai, Y. Successful treatment of myelodysplastic syndrome with 1-β-D-arabinofuranosylcytosinc-5′ -stearyl phosphate. Leukemia Research, 14: 1067, 1990.
49. Aquino, A., Hartman, K.D., Knode, M.C., Grant, S., Huang, K.P., Niu, C.H., and Glazer, R.I. Role of protein kinase C in phosphorylation of vinculin in adriamycin resistant HL-60 leukemia cells. Cancer Research, 48: 3324-3329, 1988.